Clinical Trial Update: DAA in the Risk of Recurrence After Curative Treatment of HCC [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating direct-acting antivirals for reducing recurrence after curative treatment of hepatocellular carcinoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Direct-Acting Antiviral (DAA)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Hepatocellular Carcinoma | Phase 4 | Status: WITHDRAWN